With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. | Novo ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

The Association of the British Pharmaceutical Industry (ABPI) reinstated Novo Nordisk’s membership in the group. 1 The company had previously been subjected to a two-year suspension of its membership, ...

Danish company Novo Nordisk's membership in a UK pharmaceutical industry body has been restored after a two-year suspension ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...